Background: Corticosteroids are the most common agents used in the treatment of alopecia areata (AA), however, their long-term use is associated with severe side effects. Therefore, other immunosuppressive agents have been tried and azathioprine appears to be an effective and promising alternative. Objective: The main objective of this study was to compare the efficacy of 300 mg once weekly azathioprine pulse (WAP) and 5 mg betamethasone on 2 consecutive days every week in the management of AA. Materials and Methods: In this open-label, randomized comparative study, 50 patients of AA with >10% scalp area involvement were treated with either 300 mg WAP or 5 mg betamethasone on 2 consecutive days every week for 4 months or till complete scalp hair regrowth and followed up for next 5 months. Primary efficacy parameters were average percentage scalp hair regrowth and change in average Severity of Alopecia Tool (SALT) score at 4 months. Results: Twenty patients in WAP group and 21 patients in betamethasone group completed the study. The median percent scalp hair regrowth and the median change in SALT score was 44.52 and 9.5 in WAP group compared to 71.43 and 14 in betamethasone group at 4-month, respectively, which were statistically similar in two groups, however, side effects were significantly higher in betamethasone group. On further follow-up at 9 months, 10 (50%) patients in WAP group and 13 (62%) patients in betamethasone group achieved complete hair regrowth. Lack of control group was a limitation of our study. Conclusion: WAP and betamethasone therapy, both appear to be effective in the treatment of AA. However, betamethasone caused several side effects; therefore, WAP can be used as a better alternative to corticosteroids in AA.
Introduction
Alopecia areata (AA) is a recurrent noncicatricial, autoimmune, chronic inflammatory patchy hair loss on the scalp and/or body. [1] Oral corticosteroids have shown high efficacy in moderate-to-severe disease, however, their long-term use results in serious side effects. Azathioprine has been shown to be efficacious in the treatment of this disease. [2] Pulse regimens of immunosuppressive agents have been used in various immune-mediated dermatological conditions such as lichen planus, vitiligo, and parthenium dermatitis, with good results, favorable side effect profile, better compliance, and reduced cost of treatment. [3] [4] [5] [6] [7] [8] Oral and intravenous corticosteroid pulse therapy has been used in the treatment of AA. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Weekly azathioprine pulse (WAP) therapy has been shown to have better compliance and reduced cost of treatment, yet comparable efficacy, when compared to daily azathioprine in parthenium dermatitis. [7, 8] In this open-label, randomized controlled, blinded, comparative and prospective study, we evaluated the effectiveness and side effect profile of WAP and betamethasone 5 mg on 2 days every week in the treatment of moderate-to-severe AA.
Materials and Methods
The study was approved by the Institutional Ethics Committee and written informed consent was obtained from each patient before enrollment.
Fifty consecutive patients of AA attending the outpatient department of our center were recruited. Patients of routine laboratory investigations such as complete blood counts, liver and renal function tests, routine and microscopic urine and stool examination, chest X-ray, and electrocardiogram were performed. Female patients were counseled about the need for contraception during the treatment period and 3 months following treatment. Complete blood count and liver and renal function tests were repeated on follow-up at every 4 weeks for initial 3 months and then every 8 weeks.
Primary efficacy parameters were comparison of average percentage scalp hair regrowth, average change in SALT score from baseline and side effects in two groups at the end of 4 months of treatment. 
Results
A total of 50 patients, 36 males and 14 females, between 18 and 46 years of age (mean age 26.6 ± 7.38 years) were included in the study. There were 25 patients in each group of which 20 patients in azathioprine pulse and 21 patients in betamethasone group completed the study [ Figure 1 ]. Five patients in azathioprine group and 4 in betamethasone group were lost to follow-up. Three patients were lost to follow-up due to change in residence and inability to follow-up. One patient shifted to alternative form of therapy after taking 2 weeks of treatment and five patients could not be contacted despite repeated attempts. The demographic data of the two groups were comparable [ Table 1 ]. The per-protocol analysis of the outcome was done.
Primary efficacy parameter
The median SALT score at baseline (WAP=24 ; betamethasone group=19 [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] ) were comparable ≥18 years of age, with AA affecting ≥10% scalp area for at least 3 months, were included in the study [ Table 1 ]. Patients having significant spontaneous regrowth of terminal hair, history of use of topical or intralesional therapy in the past 1 month and/or phototherapy and/or systemic therapy in the last 2 months, uncontrolled renal, hepatic, hematological or heart disease, or absolute contraindication to corticosteroids or azathioprine were excluded. Patients with alopecia universalis and pregnant or lactating women were also excluded. The diagnosis of AA in each patient was confirmed clinically by two dermatologists.
Recruited patients were randomized into two groups using random number table generated online, to receive either 300 mg azathioprine once weekly (WAP) or 5 mg betamethasone on 2 consecutive days every week for at least 4 months or till complete regrowth, whichever was earlier.
Patients showing no regrowth or further decline at 4 months were shifted to a combination therapy consisting azathioprine 100 mg daily and betamethasone 5 mg on 2 consecutive days in a week. The treatment was withdrawn in patients who achieved complete scalp hair regrowth and they were further followed up for 5 months.
Clinical details of each patient were recorded and severity of the disease was determined using severity of alopecia tool (SALT) score. [11] Baseline photographs of the standard 4 views of scalp under standard lighting conditions with a standard camera and camera settings were taken at first and subsequent visits. Baseline 
Discussion
Corticosteroids have been the most commonly used agent in the treatment of AA. These have been used in various doses and regimens with a success rate varying from 47% to 81.3%. [9] [10] [11] [12] [13] [14] [22] [23] [24] [25] [26] [27] Pulse regimens of corticosteroids with methylprednisolone and dexamethasone used as monthly as well as weekly doses have resulted in improvements ranging from 37.8% to 81.3%. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] 27] Side effects are considered to be fewer with pulse regimens than daily corticosteroid doses [ Table 3 ]. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Betamethasone pulse has been used in a dose of 5 mg twice in a week in 16 patients of extensive AA, of which 12 (75%) patients experienced good to complete regrowth after 6 months of treatment, while the hair growth was unsatisfactory in 2 (12.5%) patients and 2 patients did not show any regrowth. [11] Jang et al. performed a comparative study of oral cyclosporine (n=51) and betamethasone mini-pulse therapy (n=37) and reported ≥50% of terminal hair regrowth in 54.9% and 34.8% patients, respectively. [21] Although the corticosteroids used in various regimens have shown good response but have caused side effects even when used in pulsed regimens, and in some patients, the therapy had to be discontinued due to these side effects. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Azathioprine has been shown to be efficacious in the treatment of AA with lesser side effects. [2] In our study, we used betamethasone 5 mg twice in a week and compared it with weekly 300 mg doses of azathioprine. Betamethasone is a long-acting corticosteroid (plasma half-life=300 min) and a dose of 0.75 mg is considered as an equivalent dose to 5 mg of prednisolone. Weekly 300 mg of azathioprine was used to improve the compliance and to reduce the cost of treatment.
On comparison with previous studies, our betamethasone group patients had >75% hair regrowth in 62% patients, which was comparable to Senila et al., Nakajima et [10, 12, 13, [17] [18] [19] but our results were better than the results reported by Seiter et al., Jang et al., and Staumont-Salle et al., which can be explained by a shorter duration of therapy in these studies. [14, 15, 21] Although corticosteroid-induced side effects were more frequently observed in our study than studies by Nakajima et al., Friedli et al., Seiter et al., Lalosevic et al., and Staumont-Salle et al., probably because of use of high dose shorter courses of corticosteroids in these studies, which also resulted in higher frequency of palpitations, headache, nausea, and dizziness in their studies. [12] [13] [14] [15] 21, 27] Weight gain, Cushingoid appearance, and transient gastrointestinal discomfort were the most common side effects noted in our series as also with Khaitan et al. and Jang et al. [11, 21] Relapse rate [ [12] [13] [14] [18] [19] Azathioprine, a purine antagonist, has been used in the treatment of AA. [28] In a study by Farshi et al., on 20 patients with moderate-to-severe AA, azathioprine in the dose of 2 mg/kg/day was administered.
[2] There was 52.3% mean regrowth with a significant reduction in mean hair loss (72.7% to 33.5%) after 6 months of treatment and treatment had to be discontinued in one patient due to deranged liver function test. In our study, the mean hair regrowth was 44.52% which was comparable to the study by Farshi et al., however, none of the patients in our study experienced serious side effects warranting discontinuation of therapy, which suggested safety of weekly azathioprine regimen. The relapse rate and long-term follow-up were not systematically documented in the study by Farshi et al. In our study, one patient had relapse of disease after 2 months of discontinuing treatment. The thiopurine methyltransferase (TPMT) estimation was not done due to lack of laboratory facilities. Moreover, it has Senila et al. [12] 32 500 mg infusion of methylprednisolone on 3 days every month for 3 months 26 (81.3%) Facial flushing (17) , headache and dizziness (9) , asthenia (5), and palpitations (6) Nakajima et al. [13] 139
Single cycle of 3 days methylprednisolone 500 mg infusion 59.4% in disease duration <6 months, 15.8% in disease duration >6 months No serious side effects Friedli et al. [14] 45
Single cycle of 3 days methylprednisolone 500 mg infusion
(65%) No serious side effects
Seiter et al. [15] 30 500 mg infusion of methylprednisolone on 3 days every month for 3 months
(40%)
No serious side effects Staumont-Sallé et al. [16] 30 500 mg infusion of methylprednisolone on 3 days every month for 3 months 10 (33.3%) Tiredness (11), headache and flush (9), nausea and vomiting (7), and transient hyperglycemia (6) Sharma and Gupta [17] 30
5 mg dexamethasone two consecutive days every week 16 (63.3%) Minor side effects (8) Lalosevic et al. [18] Yeo et al. [19] 82 Methylprednisolone, 1 g/day, twice a day for 3 consecutive days for adults and 10 mg/kg/day weekly for 3 weeks for children for 6 months 53 (64.6%) GI discomfort, headache, dizziness, facial flushing, and palpitation in 16 (19.5%) patients
Yoshimasu et al. [20] 55 500 mg/day of methylprednisolone infusion for 3 days for 6 months Group 1 (<25%, 25%-49% hair loss): 100% growth Group 2 (50%-74%, 75%-99% hair loss):83% and 82% growth Myalgia and numbness (10), limbs edema (4), stomach discomfort (2), infection (2), arthralgia (1), burning sensation (1) Khaitan et al. [11] 16 Betamethasone mini-pulse therapy for 6 months 12 (75%) Cushingoid facies and weight gain (2), acneiform eruption (2), mild gastric discomfort (3) Jang et al. [21] 37
Betamethasone mini-pulse therapy for 3 months 14 (37.8%) Weight gain (11) , facial edema (9), acneiform eruption (6), GI symptoms (4), headache/dizziness (4), skin atrophy (2) GI: Gastrointestinal been shown that prior estimation of TPMT does not predict azathioprine-induced side effect/toxicity and routine hematological and biochemical investigations are adequate for follow-up monitoring. [29, 30] In addition, a lower frequency of mutant TPMT alleles have been shown in Southwest Asian population (India, Pakistan), which further reduced the necessity of TPMT levels estimation. [31] Lack of a placebo group was a limitation of our study.
Conclusion
Both weekly betamethasone and WAP therapy appear to be effective in the treatment of AA. Although more patients in betamethasone group had regrowth after 4 months of treatment, which was associated with a higher global assessment score in this group, this difference was not statistically significant (P=0.15). However, several patients in betamethasone group had corticosteroids induced side effects; therefore, azathioprine can be used as a better tolerated and effective substitute for corticosteroids, particularly in patients who cannot be treated with corticosteroids due to any contraindication or to avoid corticosteroid-induced side effects. Further studies, however, are needed to confirm our findings.
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